Arbutus Biopharma (ABUS) Options Chain & Prices $4.56 -0.18 (-3.80%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$4.56 0.00 (-0.11%) As of 07/17/2026 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Options Chain Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABUS Put and Call Options List 3/19/2027 1/15/2027 12/18/2026 9/18/2026 8/21/2026 Options Date Put and Call Options Put Options Call Options Options Type All In The Money Out of The Money Moneyness With Volume Without Volume All Volume Strike Price Min Strike Price Max Export ExpiresStrike PriceClose PricePut/CallVolumeVolume AskVolume BidOpen InterestImplied VolatilityDeltaTrades8/21/2026$4.00$0.170Put10 - - 130(+130)74.46% (-3.39%)-0.24427918/21/2026$4.00$0.743Call10 - - 72(+0)74.46% (-3.39%)0.75713318/21/2026$5.00$0.258Call338251029(+31)74.30% (+2.67%)0.3953635End-of-day options data provided by Trade Alert and Intrinio. Related Companies and Tools Related Companies GPCR Options RCUS Options ARQT Options ADPT Options BEAM Options RARE Options IDYA Options ELVN Options VERA Options QURE Options Options Chain Tools Short Interest TrackerShort Interest IncreasesShort Interest DecreasesUnusual Call VolumeUnusual Put Volume This page (NASDAQ:ABUS) was last updated on 7/19/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABUS Stock Alerts